Spread | 1.04 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 204.17 |
Open | 199.87 |
1-Year Change | -34.51% |
Day's Range | 192.39 - 199.87 |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The Company’s lead product candidate, MGL-3196 (resmetirom), is a liver-directed, selective thyroid hormone receptor-ß (THR-ß) agonist for the treatment of non-alcoholic steatohepatitis (NASH)and heterozygous familial hypercholesterolemia (HeFH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and HeFH.
BRIEF: For the fiscal year ended 31 December 2021, Madrigal Pharmaceuticals Inc revenues was not reported. Net loss increased 20% to $241.8M. Higher net loss reflects R & D increase of 11% to $194.5M (expense), G & A increase from $10M to $21.1M (expense), Stock-based Compensation in SGA increase of 36% to $16.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$13.09 to -$14.63.
Common Stock $.0001 Par, 10/10, 100M auth., 42,166,779 issd. Insiders control approx. 37.8%. IPO: 2/06/07, 5M shares @ $10 per share by Bear, Stearns & Co. Inc.